MARKET

MESO

MESO

Mesoblast
NASDAQ
2.545
-0.045
-1.74%
Closed 16:49 09/30 EDT
OPEN
2.560
PREV CLOSE
2.590
HIGH
2.690
LOW
2.530
VOLUME
94.74K
TURNOVER
--
52 WEEK HIGH
7.28
52 WEEK LOW
2.140
MARKET CAP
331.08M
P/E (TTM)
-3.6151
1D
5D
1M
3M
1Y
5Y
Mesoblast Submits New Information to US FDA on Items in Complete Response Letter to Biologics License Application for Remestemcel-L
Mesoblast Submits New Information to US FDA on Items in Complete Response Letter to Biologics License Application for Remestemcel-L
MT Newswires · 9h ago
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022
Upgrades
Benzinga · 09/06 14:09
Piper Sandler Initiates Coverage On Mesoblast with Overweight Rating, Announces Price Target of $7
Piper Sandler analyst Edward Tenthoff initiates coverage on Mesoblast (NASDAQ:MESO) with a Overweight rating and announces Price Target of $7.
Benzinga · 09/06 10:42
Piper Sandler Starts Mesoblast at Overweight With $7 Price Target
Piper Sandler Starts Mesoblast at Overweight With $7 Price Target
MT Newswires · 09/06 07:03
Mesoblast GAAP EPS of -$0.14, revenue of $10.21M
Mesoblast press release (NASDAQ:<a href="https...
Seekingalpha · 08/31 09:16
Mesoblast's Fiscal 2022 Loss Narrows, Revenue Rises
Mesoblast's Fiscal 2022 Loss Narrows, Revenue Rises
MT Newswires · 08/31 03:55
Jane Bell Joins Mesoblast Board
NEW YORK, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has appointed Jane Bell to its Board of Directors. Ms Bell is a banking ...
GlobeNewswire · 08/18 11:00
Appendix 4C Quarterly Activity Report
Mesoblast Operational and Financial Highlights for Quarter Ended June 30, 2022NEW YORK, July 29, 2022 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an ...
GlobeNewswire · 07/29 11:05
More
About MESO
Mesoblast Limited is an Australia-based company that is engaged in the development of regenerative medicine products. The Company’s primary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It has applied its mesenchymal lineage cell technology platform to the allogeneic cellular medicines portfolio in the industry. Its technology addresses multiple inflammatory conditions with unmet medical needs. The Company’s portfolio of Phase III product candidates comprises remestemcel-L for steroid-refractory acute graft versus host disease (acute GVHD), as well as for the treatment of moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection, Revascor for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. The Company’s subsidiaries include Mesoblast, Inc., Mesoblast International Sarl, Mesoblast Australia Pty Ltd, Mesoblast UK Ltd and BeiCell Ltd.

Webull offers kinds of Mesoblast limited (ADR) stock information, including NASDAQ:MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.